Indication

Primary mediastinal large B-cell lymphoma

Primary mediastinal large B-cell lymphoma is an aggressive, distinct subtype of non-Hodgkin mature B-cell neoplasm that originates from thymic medullary B cells within the anterior mediastinum. Read more about Primary mediastinal large B-cell lymphoma

9 drugs 4 manufacturers

Advertisement

Drugs that treat it

Common Primary mediastinal large B-cell lymphoma therapies.

Showing 1–9 of 9 drugs

KEYTRUDA (pembrolizumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with Primary mediastinal large B-cell lymphoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Primary mediastinal large B-cell lymphoma.

Primary mediastinal large B-cell lymphoma is an aggressive, distinct subtype of non-Hodgkin mature B-cell neoplasm that originates from thymic medullary B cells within the anterior mediastinum.

It most commonly affects adolescents and young adults, demonstrating a marked female predominance.

Pathophysiologically, it shares molecular and genetic features with classic Hodgkin lymphoma, frequently exhibiting compartmentalizing fibrosis, constitutional NF-?B activation, and alterations in chromosome 9p24.1 that lead to PD-L1 overexpression.

Clinically, it typically presents as a rapidly expanding, bulky anterior mediastinal mass that directly invades adjacent thoracic structures, frequently causing cough, dyspnea, pleural or pericardial effusions, and superior vena cava syndrome.

Personalize your experience

Follow Primary mediastinal large B-cell lymphoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it